Pharmacokinetics of endoxifen and tamoxifen in female mice: implications for comparative in vivo activity studies.

PubWeight™: 0.78‹?›

🔗 View Article (PMC 4343319)

Published in Cancer Chemother Pharmacol on October 16, 2014

Authors

Joel M Reid1, Matthew P Goetz, Sarah A Buhrow, Chad Walden, Stephanie L Safgren, Mary J Kuffel, Kathryn E Reinicke, Vera Suman, Paul Haluska, Xiaonan Hou, Matthew M Ames

Author Affiliations

1: Department of Oncology, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA.

Associated clinical trials:

Endoxifen in Adults With Hormone Receptor Positive Solid Tumors | NCT01273168

Z-Endoxifen Hydrochloride in Treating Patients With Metastatic or Locally Recurrent Estrogen Receptor-Positive Breast Cancer | NCT01327781

Articles cited by this

Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst (2003) 8.66

CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst (2005) 5.92

CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial. J Natl Cancer Inst (2012) 5.27

Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment. Clin Pharmacol Ther (2006) 4.81

CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients. J Natl Cancer Inst (2012) 4.54

Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther (2004) 3.84

Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen. Breast Cancer Res Treat (2004) 3.40

Paroxetine controlled release in the treatment of menopausal hot flashes: a randomized controlled trial. JAMA (2003) 3.08

Endoxifen (4-hydroxy-N-desmethyl-tamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen. Cancer Chemother Pharmacol (2005) 2.41

Tamoxifen metabolite concentrations, CYP2D6 genotype, and breast cancer outcomes. Clin Pharmacol Ther (2011) 2.09

Activity levels of tamoxifen metabolites at the estrogen receptor and the impact of genetic polymorphisms of phase I and II enzymes on their concentration levels in plasma. Clin Pharmacol Ther (2011) 1.98

The tamoxifen metabolite, endoxifen, is a potent antiestrogen that targets estrogen receptor alpha for degradation in breast cancer cells. Cancer Res (2009) 1.94

Effects of CYP2D6 and SULT1A1 genotypes including SULT1A1 gene copy number on tamoxifen metabolism. Ann Oncol (2007) 1.55

Oxidative stress and AP-1 activity in tamoxifen-resistant breast tumors in vivo. J Natl Cancer Inst (2000) 1.50

Metabolites of tamoxifen in animals and man: identification, pharmacology, and significance. Breast Cancer Res Treat (1982) 1.48

Tamoxifen antiestrogens. A comparison of the activity, pharmacokinetics, and metabolic activation of the cis and trans isomers of tamoxifen. J Steroid Biochem (1982) 1.41

CYP2D6 metabolism and patient outcome in the Austrian Breast and Colorectal Cancer Study Group trial (ABCSG) 8. Clin Cancer Res (2012) 1.33

Evaluation of the antitumour activity of the non-steroidal antioestrogen monohydroxytamoxifen in the DMBA-induced rat mammary carcinoma model. Eur J Cancer (1980) 1.27

Hydroxylated metabolites of tamoxifen are formed in vivo and bound to estrogen receptor in target tissues. J Biol Chem (1981) 1.20

Quantification of tamoxifen and three metabolites in plasma by high-performance liquid chromatography with fluorescence detection: application to a clinical trial. J Chromatogr B Analyt Technol Biomed Life Sci (2003) 1.17

Selective deficiency of debrisoquine 4-hydroxylase activity in mouse liver microsomes. J Pharmacol Exp Ther (1997) 1.04

Enhanced bioavailability of tamoxifen after oral administration of tamoxifen with quercetin in rats. Int J Pharm (2006) 1.04

Orally administered endoxifen is a new therapeutic agent for breast cancer. Breast Cancer Res Treat (2010) 1.00

Functional expression and comparative characterization of nine murine cytochromes P450 by fluorescent inhibition screening. Drug Metab Dispos (2008) 0.97

Endoxifen, the active metabolite of tamoxifen, is a substrate of the efflux transporter P-glycoprotein (multidrug resistance 1). Drug Metab Dispos (2010) 0.94

Influence of CYP2D6-genotype on tamoxifen efficacy in advanced breast cancer. Breast Cancer Res Treat (2013) 0.93

Implications of tamoxifen metabolism in the athymic mouse for the study of antitumor effects upon human breast cancer xenografts. Eur J Cancer Clin Oncol (1989) 0.91

Reversible and irreversible inhibition of CYP3A enzymes by tamoxifen and metabolites. Xenobiotica (2002) 0.87

Clinical pharmacokinetics of endocrine agents used in advanced breast cancer. Clin Pharmacokinet (1992) 0.86

Determination of clinically therapeutic endoxifen concentrations based on efficacy from human MCF7 breast cancer xenografts. Breast Cancer Res Treat (2013) 0.86

Metabolism of human cytochrome P450 marker substrates in mouse: a strain and gender comparison. Xenobiotica (2004) 0.86

Interactions of tamoxifen, N-desmethyltamoxifen and 4-hydroxytamoxifen with P-glycoprotein and CYP3A. Biopharm Drug Dispos (2004) 0.78

Articles by these authors

Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol (2005) 6.90

Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA (2009) 5.05

The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat (2006) 4.35

Trends in mastectomy rates at the Mayo Clinic Rochester: effect of surgical year and preoperative magnetic resonance imaging. J Clin Oncol (2009) 4.13

Tamoxifen use in postmenopausal breast cancer: CYP2D6 matters. J Clin Oncol (2012) 3.61

Immune-induced epithelial to mesenchymal transition in vivo generates breast cancer stem cells. Cancer Res (2009) 3.30

Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study. Lancet Oncol (2009) 3.21

Genome-wide associations and functional genomic studies of musculoskeletal adverse events in women receiving aromatase inhibitors. J Clin Oncol (2010) 3.02

Retracted Phase II study of the anti-insulin-like growth factor type 1 receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small-cell lung cancer. J Clin Oncol (2009) 2.75

Clinical implementation of pharmacogenomics: overcoming genetic exceptionalism. Lancet Oncol (2010) 2.52

Targeted delivery of gemcitabine to pancreatic adenocarcinoma using cetuximab as a targeting agent. Cancer Res (2008) 2.20

Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study. J Clin Oncol (2009) 2.06

The tamoxifen metabolite, endoxifen, is a potent antiestrogen that targets estrogen receptor alpha for degradation in breast cancer cells. Cancer Res (2009) 1.94

An NQO1- and PARP-1-mediated cell death pathway induced in non-small-cell lung cancer cells by beta-lapachone. Proc Natl Acad Sci U S A (2007) 1.92

Potential applications for circulating tumor cells expressing the insulin-like growth factor-I receptor. Clin Cancer Res (2007) 1.84

Multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer: TBCRC 006. J Clin Oncol (2013) 1.81

Radiotherapy and adjuvant trastuzumab in operable breast cancer: tolerability and adverse event data from the NCCTG Phase III Trial N9831. J Clin Oncol (2009) 1.80

Painful metastases involving bone: feasibility of percutaneous CT- and US-guided radio-frequency ablation. Radiology (2002) 1.79

Mu-calpain activation in beta-lapachone-mediated apoptosis. Cancer Biol Ther (2003) 1.76

Expression of insulin receptor isoform A and insulin-like growth factor-1 receptor in human acute myelogenous leukemia: effect of the dual-receptor inhibitor BMS-536924 in vitro. Cancer Res (2009) 1.71

IGF-1 receptor inhibitors in clinical trials--early lessons. J Mammary Gland Biol Neoplasia (2008) 1.62

A phase I study of 17-allylaminogeldanamycin in relapsed/refractory pediatric patients with solid tumors: a Children's Oncology Group study. Clin Cancer Res (2007) 1.61

Phase 0 clinical chemoprevention trial of the Akt inhibitor SR13668. Cancer Prev Res (Phila) (2011) 1.57

Phase I and pharmacokinetic study of two different schedules of oxaliplatin, irinotecan, Fluorouracil, and leucovorin in patients with solid tumors. J Clin Oncol (2003) 1.54

A phase I trial of twice-weekly 17-allylamino-demethoxy-geldanamycin in patients with advanced cancer. Clin Cancer Res (2006) 1.51

Painful metastases involving bone: percutaneous image-guided cryoablation--prospective trial interim analysis. Radiology (2006) 1.46

Phase I trial of oral fenretinide in children with high-risk solid tumors: a report from the Children's Oncology Group (CCG 09709). J Clin Oncol (2006) 1.43

Calcium-dependent modulation of poly(ADP-ribose) polymerase-1 alters cellular metabolism and DNA repair. J Biol Chem (2006) 1.43

Clinical trial designs for prospective validation of biomarkers. Am J Pharmacogenomics (2005) 1.43

Pediatric phase I trial and pharmacokinetic study of vorinostat: a Children's Oncology Group phase I consortium report. J Clin Oncol (2010) 1.42

HER receptor signaling confers resistance to the insulin-like growth factor-I receptor inhibitor, BMS-536924. Mol Cancer Ther (2008) 1.40

The genomic landscape of small intestine neuroendocrine tumors. J Clin Invest (2013) 1.37

Tumorgrafts as in vivo surrogates for women with ovarian cancer. Clin Cancer Res (2014) 1.35

CYP2D6 metabolism and patient outcome in the Austrian Breast and Colorectal Cancer Study Group trial (ABCSG) 8. Clin Cancer Res (2012) 1.33

Toxicology and pharmacokinetics of 1-methyl-d-tryptophan: absence of toxicity due to saturating absorption. Food Chem Toxicol (2007) 1.32

Image-guided ablation of painful metastatic bone tumors: a new and effective approach to a difficult problem. Skeletal Radiol (2005) 1.30

Gemcitabine pharmacogenomics: cytidine deaminase and deoxycytidylate deaminase gene resequencing and functional genomics. Clin Cancer Res (2006) 1.30

Histone deacetylase inhibitors and paclitaxel cause synergistic effects on apoptosis and microtubule stabilization in papillary serous endometrial cancer cells. Mol Cancer Ther (2006) 1.27

Cancer and pregnancy: parallels in growth, invasion, and immune modulation and implications for cancer therapeutic agents. Mayo Clin Proc (2009) 1.25

Percutaneous image-guided cryoablation of painful metastases involving bone: multicenter trial. Cancer (2012) 1.25

Coprescription of tamoxifen and medications that inhibit CYP2D6. J Clin Oncol (2010) 1.21

Hormone response in ovarian cancer: time to reconsider as a clinical target? Endocr Relat Cancer (2012) 1.20

Phase II study of oral capsular 4-hydroxyphenylretinamide (4-HPR/fenretinide) in pediatric patients with refractory or recurrent neuroblastoma: a report from the Children's Oncology Group. Clin Cancer Res (2011) 1.16

Safety, pharmacokinetics, and pharmacodynamics of the insulin-like growth factor type 1 receptor inhibitor figitumumab (CP-751,871) in combination with paclitaxel and carboplatin. J Thorac Oncol (2009) 1.14

Variation in anastrozole metabolism and pharmacodynamics in women with early breast cancer. Cancer Res (2010) 1.14

The insulin-like growth factor system in cancer. Endocrinol Metab Clin North Am (2012) 1.14

Primer on medical genomics. Part XII: Pharmacogenomics--general principles with cancer as a model. Mayo Clin Proc (2004) 1.14

Colonic polyposis and neoplasia in Cowden syndrome. Mayo Clin Proc (2011) 1.14

Malignant melanoma in the 21st century: the emerging molecular landscape. Mayo Clin Proc (2008) 1.13

Randomized trial of tamoxifen alone or combined with fluoxymesterone as adjuvant therapy in postmenopausal women with resected estrogen receptor positive breast cancer. North Central Cancer Treatment Group Trial 89-30-52. Breast Cancer Res Treat (2006) 1.13

Selective estrogen receptor modulators and pharmacogenomic variation in ZNF423 regulation of BRCA1 expression: individualized breast cancer prevention. Cancer Discov (2013) 1.12

Resistance pathways relevant to insulin-like growth factor-1 receptor-targeted therapy. Curr Opin Investig Drugs (2009) 1.11

Cixutumumab. Expert Opin Investig Drugs (2009) 1.09

Automated discovery of drug treatment patterns for endocrine therapy of breast cancer within an electronic medical record. J Am Med Inform Assoc (2011) 1.09

Catalase abrogates β-lapachone-induced PARP1 hyperactivation-directed programmed necrosis in NQO1-positive breast cancers. Mol Cancer Ther (2013) 1.08

Androgen receptor-positive triple negative breast cancer: a unique breast cancer subtype. Ann Surg Oncol (2013) 1.07

Phase 1 trial of flavopiridol combined with cisplatin or carboplatin in patients with advanced malignancies with the assessment of pharmacokinetic and pharmacodynamic end points. Clin Cancer Res (2005) 1.06

Epidermal growth factor receptor and activated epidermal growth factor receptor expression in gastrointestinal carcinoids and pancreatic endocrine carcinomas. Mod Pathol (2005) 1.05

Activation of the antitumor agent aminoflavone (NSC 686288) is mediated by induction of tumor cell cytochrome P450 1A1/1A2. Mol Pharmacol (2002) 1.05

Estrogen receptor-beta sensitizes breast cancer cells to the anti-estrogenic actions of endoxifen. Breast Cancer Res (2011) 1.05

Dual IGF-1R/InsR inhibitor BMS-754807 synergizes with hormonal agents in treatment of estrogen-dependent breast cancer. Cancer Res (2011) 1.04

Heat shock protein 90 inhibition depletes LATS1 and LATS2, two regulators of the mammalian hippo tumor suppressor pathway. Cancer Res (2010) 1.03

Phase I trial of two schedules of vincristine, oral irinotecan, and temozolomide (VOIT) for children with relapsed or refractory solid tumors: a Children's Oncology Group phase I consortium study. Pediatr Blood Cancer (2010) 1.03

New tricks for old drugs: the anticarcinogenic potential of DNA repair inhibitors. J Mol Histol (2006) 1.02

TSPYL5 SNPs: association with plasma estradiol concentrations and aromatase expression. Mol Endocrinol (2013) 1.02

IGFBP ratio confers resistance to IGF targeting and correlates with increased invasion and poor outcome in breast tumors. Clin Cancer Res (2012) 1.01

Molecular analysis of metaplastic breast carcinoma: high EGFR copy number via aneusomy. Mol Cancer Ther (2008) 1.01

Phase II trial of two different irinotecan schedules with pharmacokinetic analysis in patients with recurrent glioma: North Central Cancer Treatment Group results. J Neurooncol (2008) 1.00

A phase I trial of the IGF-1R antibody Cixutumumab in combination with temsirolimus in patients with metastatic breast cancer. Breast Cancer Res Treat (2013) 0.99

Identification and characterization of genetic variation in the folylpolyglutamate synthase gene. Cancer Res (2007) 0.99

CYP2D6 genotype and tamoxifen response. Breast Cancer Res (2005) 0.99

Impact of American Society of Clinical Oncology/College of American Pathologists guideline recommendations on HER2 interpretation in breast cancer. Hum Pathol (2009) 0.99

Phase I/II trial of pyrazoloacridine and carboplatin in patients with recurrent glioma: a North Central Cancer Treatment Group trial. Invest New Drugs (2005) 0.99

Evaluation of CYP2D6 and efficacy of tamoxifen and raloxifene in women treated for breast cancer chemoprevention: results from the NSABP P1 and P2 clinical trials. Clin Cancer Res (2011) 0.98

Phase I study of 17-allylamino-17 demethoxygeldanamycin, gemcitabine and/or cisplatin in patients with refractory solid tumors. Invest New Drugs (2010) 0.98

Nonhomologous end joining is essential for cellular resistance to the novel antitumor agent, beta-lapachone. Cancer Res (2007) 0.98

Cytochrome P450 2D6 and homeobox 13/interleukin-17B receptor: combining inherited and tumor gene markers for prediction of tamoxifen resistance. Clin Cancer Res (2008) 0.95

Phase I trial and pharmacokinetics of gemcitabine in children with advanced solid tumors. J Clin Oncol (2004) 0.95

Inhibition of mitochondrial respiration as a source of adaphostin-induced reactive oxygen species and cytotoxicity. J Biol Chem (2007) 0.94

Phase I study of vorinostat in combination with temozolomide in patients with high-grade gliomas: North American Brain Tumor Consortium Study 04-03. Clin Cancer Res (2012) 0.94

A phase I trial of vorinostat and bortezomib in children with refractory or recurrent solid tumors: a Children's Oncology Group phase I consortium study (ADVL0916). Pediatr Blood Cancer (2012) 0.94